Serum Soluble CD25 in Hepatocellular Carcinoma, Shall We Able to Change the Natural History?

Journal Title: Journal of Cancer and Tumor International - Year 2017, Vol 5, Issue 4

Abstract

Background: Although hepatocellular carcinoma (HCC) is one of the most common malignancy related mortality worldwide, it can be curable if detected in early stages. Axiomatically, emergence of a new marker for early prediction of HCC could enable to apply the proper treatment strategy early in the course of the disease and therefore ameliorates the outcome. Aim: To evaluate the performance of serum soluble CD25 (sCD25) in the prediction of early HCC and compare it to α-fetoprotein (AFP); the classical biomarker of HCC. Methods: Serum levels of sCD25 and AFP were measured in three groups of population; HCC group (40 patients), cirrhosis without HCC control group (20 patients) and healthy control group (20 patients). HCC group contained 20 early and 20 late stage patients according to Tumor Lymph Node Metastasis (TNM) staging system (stage I/II and III/IV respectively). Levels of both biomarkers were compared in all groups. Predictive yield of both biomarkers for early HCC was evaluated using ROC curve analysis. Results: Level of sCD25 was significantly higher in patients with HCC than in both cirrhotic controls and healthy controls (P<0.0001and 0.013 respectively). For the presence of HCC, sensitivity and specificity of sCD25 were 90% and 84.2% respectively at a cut-off value of 7 ng/ml (AUC=0.969; P<0.0001). For prediction of early HCC in patients with cirrhosis, the optimal sCD25 cutoff level was 7.15 ng/ml with sensitivity and specificity of 90% and 60% respectively (AUC=0.717; P=0.019) while sensitivity and specificity of AFP were 70% and 85% respectively at a cut-off value of 9.85 ng/ml (AUC=0.781; P=0.002) in the same settings. Conclusion: sCD25 seems to be a reliable biomarker for early detection of HCC and therefore could enhance the outcome.

Authors and Affiliations

Eman Abdel Sameea, Talaat Zakareya, Khaled Metwaly, Anas Abdel Rahman, Howyda Mohammed Kamal, Wafaa Mohammed Abdalla

Keywords

Related Articles

MiRNA and Target Oncogene Regulation in Triple Negative Breast Cancer: An Age, Ethnic and Environmental Related Neoplastic Event

Triple-negative breast cancer is a type of aggressive breast cancer without the immunohistochemical expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor-2; with poor prognos...

Complex of Small Non-coding RNAs piR-30074 and Antago-miR-155 and miR-125b with DDMC Carrier Transforms Girardi Heart Cells into CD4+ Cells

Girardi heart cells are cell culture of right atrial cells contaminated with HeLa cervical adenocarcinoma cells. The combined cells have genotypic characteristics of cervical cancer. In this study, was investigated influ...

Pathological Study of Colorectal Cancer in Missan Province

Aims: Colorectal cancer (CRC) is a major cause of morbidity and mortality in the worldwide and also ranks as the fifth-leading malignancy and death in Iraq. This study aimed to provide a present outlook of colorectal di...

Effect of Ethanol Extract of Abrus precatorious Seed on Testosterone-Induced Benign Prostatic Hyperplasia in Adult Male Wistar Rats

Aim: To assess the effects of Abrus precatorious seed extract on prostate weight and hormonal levels (dihydrotestosterone, testosterone and estrogen) of male Wistarrats. Study Design: The study was divided into six group...

Photodynamic Therapy for Vulvar Carcinoma in situ (Case Report)

The article presents a clinical case of the successful application of photodynamic therapy with chlorine e6-based photosensitizer photolon in a patient with vulvar cancer in situ. The use of an exposure dose of light of...

Download PDF file
  • EP ID EP309100
  • DOI 10.9734/JCTI/2017/35735
  • Views 111
  • Downloads 0

How To Cite

Eman Abdel Sameea, Talaat Zakareya, Khaled Metwaly, Anas Abdel Rahman, Howyda Mohammed Kamal, Wafaa Mohammed Abdalla (2017). Serum Soluble CD25 in Hepatocellular Carcinoma, Shall We Able to Change the Natural History?. Journal of Cancer and Tumor International, 5(4), 1-7. https://europub.co.uk./articles/-A-309100